Answers are grounded in this paper and cite their sources.
The risk of developing oxaliplatin HSR should not be underestimated (8.9% of patients). The medical team's vigilance should be increased with women, younger patients and patients with prior exposure to platinum salts.
No takes yet. Share an insight, caveat, or question.
Parel et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: